vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and El Pollo Loco Holdings, Inc. (LOCO). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $126.2M, roughly 2.0× El Pollo Loco Holdings, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 6.5%, a 4.7% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 5.9%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 1.6%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
El Pollo Loco, Inc., is a restaurant chain based in the United States, specializing in Mexican-style grilled chicken. Restaurant service consists of dine-in and take-out, with some locations offering drive-through options. The company is headquartered in Costa Mesa, California, and operates about 500 company-owned and franchised restaurants in the Southwestern United States.
ANIP vs LOCO — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $126.2M |
| Net Profit | $27.5M | $8.2M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 9.7% |
| Net Margin | 11.1% | 6.5% |
| Revenue YoY | 29.6% | 5.9% |
| Net Profit YoY | 367.5% | 48.8% |
| EPS (diluted) | $1.14 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $126.2M | ||
| Q4 25 | $247.1M | $123.5M | ||
| Q3 25 | $227.8M | $121.5M | ||
| Q2 25 | $211.4M | $125.8M | ||
| Q1 25 | $197.1M | $119.2M | ||
| Q4 24 | $190.6M | $114.3M | ||
| Q3 24 | $148.3M | $120.4M | ||
| Q2 24 | $138.0M | $122.2M |
| Q1 26 | — | $8.2M | ||
| Q4 25 | $27.5M | $6.5M | ||
| Q3 25 | $26.6M | $7.4M | ||
| Q2 25 | $8.5M | $7.1M | ||
| Q1 25 | $15.7M | $5.5M | ||
| Q4 24 | $-10.3M | $6.0M | ||
| Q3 24 | $-24.2M | $6.2M | ||
| Q2 24 | $-2.3M | $7.6M |
| Q1 26 | — | 9.7% | ||
| Q4 25 | 14.1% | 8.3% | ||
| Q3 25 | 15.9% | 9.4% | ||
| Q2 25 | 6.6% | 9.0% | ||
| Q1 25 | 13.3% | 7.5% | ||
| Q4 24 | -2.3% | 7.9% | ||
| Q3 24 | -13.8% | 8.4% | ||
| Q2 24 | 3.7% | 10.1% |
| Q1 26 | — | 6.5% | ||
| Q4 25 | 11.1% | 5.3% | ||
| Q3 25 | 11.7% | 6.1% | ||
| Q2 25 | 4.0% | 5.6% | ||
| Q1 25 | 8.0% | 4.6% | ||
| Q4 24 | -5.4% | 5.2% | ||
| Q3 24 | -16.3% | 5.1% | ||
| Q2 24 | -1.7% | 6.2% |
| Q1 26 | — | $0.27 | ||
| Q4 25 | $1.14 | $0.22 | ||
| Q3 25 | $1.13 | $0.25 | ||
| Q2 25 | $0.36 | $0.24 | ||
| Q1 25 | $0.69 | $0.19 | ||
| Q4 24 | $-0.45 | $0.21 | ||
| Q3 24 | $-1.27 | $0.21 | ||
| Q2 24 | $-0.14 | $0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $3.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $302.5M |
| Total Assets | $1.4B | $609.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $3.9M | ||
| Q4 25 | $285.6M | $6.2M | ||
| Q3 25 | $262.6M | $10.9M | ||
| Q2 25 | $217.8M | $9.0M | ||
| Q1 25 | $149.8M | $4.3M | ||
| Q4 24 | $144.9M | $2.5M | ||
| Q3 24 | $145.0M | $7.9M | ||
| Q2 24 | $240.1M | $10.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $51.0M | ||
| Q3 25 | — | $61.0M | ||
| Q2 25 | — | $69.0M | ||
| Q1 25 | — | $73.0M | ||
| Q4 24 | — | $71.0M | ||
| Q3 24 | — | $76.0M | ||
| Q2 24 | — | $87.0M |
| Q1 26 | — | $302.5M | ||
| Q4 25 | $540.7M | $291.1M | ||
| Q3 25 | $505.8M | $282.9M | ||
| Q2 25 | $436.8M | $274.2M | ||
| Q1 25 | $418.6M | $265.7M | ||
| Q4 24 | $403.7M | $260.7M | ||
| Q3 24 | $405.9M | $255.2M | ||
| Q2 24 | $455.8M | $248.6M |
| Q1 26 | — | $609.1M | ||
| Q4 25 | $1.4B | $606.6M | ||
| Q3 25 | $1.4B | $602.7M | ||
| Q2 25 | $1.3B | $596.8M | ||
| Q1 25 | $1.3B | $590.5M | ||
| Q4 24 | $1.3B | $592.0M | ||
| Q3 24 | $1.3B | $590.0M | ||
| Q2 24 | $920.8M | $593.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | 0.30× | ||
| Q2 24 | — | 0.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $13.9M | ||
| Q3 25 | $44.1M | $15.3M | ||
| Q2 25 | $75.8M | $14.1M | ||
| Q1 25 | $35.0M | $4.7M | ||
| Q4 24 | $15.9M | $5.6M | ||
| Q3 24 | $12.5M | $13.0M | ||
| Q2 24 | $17.4M | $17.0M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $5.1M | ||
| Q3 25 | $38.0M | $9.9M | ||
| Q2 25 | $71.8M | $9.1M | ||
| Q1 25 | $32.5M | $1.3M | ||
| Q4 24 | $13.5M | $1.1M | ||
| Q3 24 | $7.7M | $9.1M | ||
| Q2 24 | $13.0M | $10.4M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 4.1% | ||
| Q3 25 | 16.7% | 8.2% | ||
| Q2 25 | 34.0% | 7.2% | ||
| Q1 25 | 16.5% | 1.1% | ||
| Q4 24 | 7.1% | 1.0% | ||
| Q3 24 | 5.2% | 7.6% | ||
| Q2 24 | 9.4% | 8.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 7.1% | ||
| Q3 25 | 2.7% | 4.4% | ||
| Q2 25 | 1.9% | 4.0% | ||
| Q1 25 | 1.3% | 2.8% | ||
| Q4 24 | 1.3% | 3.9% | ||
| Q3 24 | 3.2% | 3.2% | ||
| Q2 24 | 3.2% | 5.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 2.13× | ||
| Q3 25 | 1.66× | 2.08× | ||
| Q2 25 | 8.87× | 1.99× | ||
| Q1 25 | 2.23× | 0.86× | ||
| Q4 24 | — | 0.95× | ||
| Q3 24 | — | 2.11× | ||
| Q2 24 | — | 2.22× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
LOCO
Segment breakdown not available.
